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SUMMARY AT A GLANCE 
Non-expansile Lung (NEL) often complicates malignant pleural effusion management.  This 
multicentre study identifies significant limitations in radiographic NEL detection and an 
association between NEL and adverse survival. These findings are relevant to clinical 
practice and should be considered in future trial design.  
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Background and objective: Non-expansile lung (NEL) frequently complicates 
management of malignant pleural effusion (MPE) and is an important factor in clinical 
practice and trials. NEL is frequently diagnosed on a single radiographic observation, 
but neither the inter-observer agreement of this approach nor the prognostic importance 
of NEL in MPE have been reported. 
 
Methods: A multicentre retrospective cohort study was performed in 2 UK pleural 
centres. NEL was defined as <50% pleural re-apposition on post-drainage radiographs 
by primary and secondary assessors at each site.  Inter-observer agreement was assessed 
by Cohen’s Kappa (). Kaplan-Meier methodology and multivariate Cox models were 
used to assess the prognostic impact of NEL vs no NEL and ‘Complete NEL’ vs 
‘Complete expansion’, based on a single assessor’s results from each site. 
 
Results: NEL was identified by the primary assessor in 33/97 (34%) in Cohort 1 and 
15/86 (17%) in Cohort 2. Inter-observer agreement between assessors was only fair-to-
moderate (Cohort 1 0.38 (95% CI:0.21–0.55), Cohort 2 0.51 (95% CI:0.30–0.72)). In 
both cohorts, NEL was associated with shorter median overall survival (Cohort 1: 188 
vs 371 days, Cohort 2: 192 vs 412 days). This prognostic association was independent 
in Cohort 1 (HR 2.19, 95% CI:1.31–3.66) but not Cohort 2 (HR 1.42, 95% CI:0.71–
2.87). Survival was inferior in both cohorts in cases of ‘Complete NEL’ vs ‘Complete 
Expansion’. 
 
Conclusion: Radiographic NEL is common but inter-observer agreement is only fair-to-
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moderate. NEL is associated with adverse survival. These data do not support use of 
single radiographic assessments to classify NEL. 
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Malignant Pleural Effusion (MPE) frequently leads to disabling breathlessness, 
requiring definitive palliation by one of several methods. In this regard, talc slurry 
pleurodesis (TSP) and indwelling pleural catheters (IPCs) deliver equivalent symptom 
control, based on two previously reported Phase III trials1,2. However, patients with 
known non-expansile lung (NEL), where TSP is contraindicated, were excluded from 
both studies and only small numbers with radiographically-occult NEL were included 
(6%1 and 3%2, in TIME2 and AMPLE, respectively). In the recently published IPC-
PLUS trial3, the addition of talc slurry to standard IPC care significantly improved 
pleurodesis success rates 10-weeks after catheter placement. However, in this study, a 
significant number of patients failed screening due to radiographically-defined NEL 
(41/339 (12%)), while an additional 32/250 (13%) of those recruited could not receive 
talc due to NEL that subsequently became apparent3.  
 
Radiographic detection of NEL is therefore an important factor in the planning of MPE 
treatment, and is routinely used as an eligibility criterion4, stratification factor5 and/or 
treatment determinant6 in MPE trials. However, there are limited data supporting use of 
NEL in this manner, particularly with regard to inter-observer agreement, which should 






Study Design and Patients 
A multi-centre retrospective cohort study was performed. The a priori primary objective 
was to quantify the level of inter-observer agreement associated with NEL, as classified 
by 4 experienced clinicians using the definition below, as defined by Cohen’s Kappa 
statistic. The secondary objective was to examine the relationship between NEL and 
subsequent survival, based on the output of a multivariable Cox regression model. 
Prospectively populated databases were used to identify consecutive patients treated at 
two UK pleural tertiary referral centres who underwent complete MPE drainage during 
diagnostic local anaesthetic thoracoscopy (LAT) between July 2010 and March 2018 
(Cohort 1), and July 2013 and July 2017 (Cohort 2). Cases with any missing data 
specified below were excluded. Study activities were approved by the local ethics 
committees (References: 17/SC/0351, 08/H0102/11).  This allowed use of unconsented 
linked anonymised data in Cohort 1. Patients in Cohort 2 provided written consent for 
use of their data as part of the Pleural Investigation Study, full details of which have 
been published elsewere. 
 
Data Collection 
Electronic records and digital chest radiographs (CXRs) were reviewed retrospectively. 
The presence or absence of NEL was evaluated on the post-LAT, pre-discharge CXR 
that showed the maximum expansion as judged by primary assessors at each site (GAM; 
PH). NEL was defined as <50% pleural apposition based on subjective visual estimation, 
extrapolating the British Thoracic Society (BTS) statement that pleurodesis is unlikely 
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to succeed below this value8. Blinded secondary assessors (ACK; AB) independently 
classified the same CXRs using the same definition. Post hoc, CXRs were further sub-
classified by a single assessor at each site into extreme expansion phenotypes; 
‘Complete NEL’ (where no lateral pleural apposition was achieved) and ‘Complete 
Expansion’ (where total pleural apposition was achieved). All assessors were 
experienced respiratory physicians who routinely assess CXRs for NEL in clinical 
practice. Demographics, LENT MPE prognostic score components (pleural fluid lactate 
dehydrogenase (LDH), performance status (PS), blood neutrophil-to-lymphocyte ratio 
(NLR), tumour type) acquired at/within 28 days of LAT were recorded. Overall survival 
(OS) was recorded from LAT to death (or censor).  
 
Statistical Analysis 
Patient characteristics and baseline variables were tabulated by study site; differences 
were assessed by unpaired t-test, Mann-Whitney or Fisher’s exact test as appropriate. 
Inter-observer agreement regarding NEL, between primary and secondary assessors at 
each site, was quantified by Cohen’s Kappa statistic. Kaplan-Meier curves and 
multivariable Cox regression (a priori model inputs: LDH, PS, NLR, LENT tumour risk 
score, NEL) were used to identify any association between the presence of NEL, as 
defined by the primary assessor, and OS in each cohort. For this purpose, Cohort 1 was 
used as a test set and Cohort 2 as an independent validation set. In a subsequent post hoc 
analysis, differences in OS between extreme re-expansion phenotypes (‘Complete NEL’ 
vs ‘Complete Expansion’) were compared using Kaplan-Meier methodology. Analyses 









214 eligible patients were identified. Complete data were available for 183/214 (86%: 
Cohort 1 n=97, Cohort 2 n=86); cases with any missing data were excluded (Cohort 1: 
23 LDH, 4 PS; Cohort 2: 3 LDH, 2 PS). Demographics and clinical data were broadly 
similar between cohorts (Table 1). However, more patients in Cohort 2 were male and 
had a diagnosis of MPM, and more patients were in PS group 2. Maximal lung re-
expansion was observed within 24 hours of LAT in 53/97 (55%) in Cohort 1 and 53/86 
(62%) in Cohort 2. The prevalence of NEL, based on the radiographic classification 
made by the primary assessor at each site, was 34% (33/97) in Cohort 1 and 17% 
(15/86) in Cohort 2. However, inter-observer agreement between assessors at each site 
regarding NEL was only fair-to-moderate9 (Cohort 1  0.38 (95% CI:0.21–0.55); 
Cohort 2  0.51 (95% CI:0.30–0.72)).  
 
Patients with NEL, as defined by the primary assessor, had shorter median OS than 
patients without NEL in both cohorts (Figure 1). In Cohort 1, NEL defined in this 
manner, was independently associated with adverse survival (HR 2.19, 95% CI:1.31–
3.66), but this was not replicated in Cohort 2 (HR 1.42, 95% CI:0.71–2.87 – Table 2). 
However, in a subsequent post hoc analysis, median OS was significantly shorter in 
both cohorts in cases with Complete NEL (Cohort 1, 6/97 (6%); Cohort 2, 5/86 (6%)) 
compared to those with Complete Expansion (Cohort 1, 19/97 (20%); Cohort 2, 44/86 
(51%)), see Figure 2. Figure 3 shows examples of CXRs classified by the primary 
assessor in Cohort 1 as a) NEL on the basis of <50% pleural apposition for the primary 
outcome, and examples of extreme re-expansion phenotypes used in the post hoc 
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In this retrospective, multi-centre cohort study, NEL was relatively common in patients 
following LAT, based on visual assessment of pre-discharge CXRs by experienced 
clinicians (Cohort 1 34%, Cohort 2 17%). However, the level of agreement between 
clinicians was only fair-to-moderate ( <0.5 for both cohorts). To our knowledge, this is 
the first study to report agreement between observers classifying lung re-expansion on 
CXR. The definition of NEL adopted here was based on guidance made in the 2010 
BTS Pleural Guideline, which advises that pleurodesis is unlikely to be successful in 
cases with clear evidence of NEL, as defined by <50% pleural apposition8. However, 
this statement was not designed to be a precise diagnostic criterion for NEL and other 
studies have used alternatives (e.g. <75% pleural apposition)3,10,11. A different definition 
of NEL might improve inter-observer variability, but may be less clinically relevant 
since subtle NEL might still be amenable to a pleurodesis attempt.  
 
The definition and incidence rate of NEL varies widely in previous prospective clinical 
trials of MPE, making it difficult to interpret the potential significance of our findings 
on these data and future studies. In the AMPLE trial2, which compared TSP with IPC 
management, NEL, defined pragmatically as ‘incomplete lung expansion’, was reported 
in only 3% (5/146) participants. In contrast, 32% (28/87) patients had NEL in AMPLE-
210, which compared different IPC drainage strategies, based on a definition of <75% 
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lateral apposition. Other studies report rates that lie between these extremes, possibly 
reflecting different definitions and/or exclusion criteria, e.g. 6% in TIME2 (based on 
<50% pleural apposition)1, 13% in IPC-PLUS (based on <75% pleural apposition)3,  
and 29% in the Phase III Intergroup Study (based on (<90% expansion)12. The explicit 
exclusion from most of these trials of patients with an expected survival of <3 months, 
may, in particular, inadvertently exclude most patients with NEL, given the survival 
disadvantage reported here. It does appear important whatever the true rate of NEL in 
clinical practice and future trials, that a more consistent definition is adopted and where 
possible, multiple observers are used to adjudicate on the presence of NEL, when this 
directs clinical care (e.g. the decision to instil talc or remove a chest drain) or affects 
trial recruitment eligibility.  
 
In the current study, median OS was inferior in both cohorts in patients with NEL on 
univariate analysis – this was based on the primary assessor’s adjudication and the 
definition of <50% lung re-expansion. NEL defined in this manner was also 
independently associated with adverse survival in Cohort 1 (HR for death 2.19, 95% 
CI:1.31–3.66, p=0.003), but this was not replicated in Cohort 2 (HR for death 1.42, 95% 
CI:0.71–2.87, p=0.322). This may reflect the smaller number of NEL cases in that series 
(17% (15/86) vs 34% (33/97)), reduced statistical power and a resultant type II 
statistical error. Additionally, the variability also reported in classifying NEL in this 
manner (<50% pleural apposition) leads to the obvious potential that borderline cases 
were differently classified by the primary assessors at each site. This possibility 
prompted the post hoc analysis conducted in extreme phenotypes since there is no real 
risk of misclassification in these cases. Since this analysis demonstrated significantly 
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inferior survival in cases with ‘Complete NEL’ vs those with ‘Complete Expansion’, 
see Figure 2, we conclude the prognostic effect identified is genuine.  
 
In an earlier retrospective study, Leemans et al reported similar adverse survival 
(median OS 66 days vs 169 days) in patients with MPE (due to a range of tumour types) 
who failed thoracoscopic talc pleurodesis due to NEL13.  In MPM, visceral pleural 
tumour, a frequent cause of NEL, has histrorically been associated with adverse survival 
via higher disease stage14. More recently, Bibby et al  confirmed this association based 
on radiographic NEL. In that study the HR for death was 1.80 (95% CI:1.16–2.80))11 in 
192 patients with MPM, 64 of whom (33%) developed NEL at some point during their 
disease course.  The use of serial chest radiographs over a long follow-up period in this 
study clearly differs from our own method but the observation of excess mortality is 
concordant with our own conclusions. 
 
Radiographic interpretation is a cornerstone in the management of patients with MPE. 
In patients undergoing fluid drainage, CXR findings directly determine the timing of 
talc slurry instillation and chest drain removal8. As such, variation in CXR interpretation 
regarding lung re-expansion (and the presence of NEL) is of critical importance and 
could result in futile talc slurry instillation and inappropriate prolongation of 
hospitalisation if NEL is under-recognised. Conversely, such variation may also result 
in missed opportunities to deliver talc pleurodesis and lasting symptom control if 
expansile lung is mis-classified as NEL. Although data relating a particular CXR 
definition to subsequent TSP success do not exist, our finding of only fair-to-moderate 
interobserver agreement would support the use of consensus judgments regarding lung 
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re-expansion rather than relying on a single assessor. In particular, this approach should 
be considered in clinical trial design where patients may be excluded from enrolment or 
study procedures based on a single observer’s judgement4. 
 
The level of disagreement reported here highlights the challenges involved in 
radiographic NEL assessment, even when experienced assessors are involved. 
Development of a reliable method of NEL detection should therefore be a clinical 
imperative. Evaluation of 3-dimensional lung expansion based on a 2-dimensional 
image is an inherently flawed concept and a technique which provides a global 
assessment of the pleural cavity is clearly required. To this end, a multicentre study 
addressing this challenge is currently recruiting the UK, using systematic multiplanar 
thoracic ultrasound scanning15. There is also interest in the potential use of pleural 
elastance (an intrinsic property of the pleural cavity derived from intra-pleural pressure 
change during thoracentesis) as a NEL biomarker to direct patient care16. Future 
research of novel NEL methods should also seek to establish the relationships between 
varying expansion thresholds and clinical outcomes.  
 
The retrospective design of this study made missing data inevitable and reduced the size 
of the dataset available for analysis. The inherently constrained statistical power 
increases the risk of a type II error regarding an independent association between NEL 
and survival. In addition, patient numbers also precluded sub-group analyses and 
exploration of a potential interaction between MPM disease stage, NEL and mortality, 
which is entirely plausible based on earlier studies14. A larger study would be able 
assess this important question, since the adverse survival associated with NEL may 
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reflect greater pleural tumour burden, physiological compromise or the risks of repeat 
pleural procedures and hospitalisation.   
 
Due to reliance on LAT databases, and its geographical basis in post-industrial coastal 
cities, this study included a higher proportion of patients with MPM than is encountered 
in routine practice in other areas. Since the natural course of MPM is to readily 
proliferate from parietal to visceral pleura surfaces, the generalisability of our 
prognostic findings to a more general MPE cohort should not be assumed and requires 
future validation. Additionally, in most centres, the majority of patients with 
symptomatic MPE will be managed by closed pleural drainage via some form of tube 
thoracostomy rather than open drainage at LAT. However, expansion outcomes are 
unlikely to vary meaningfully between thoracostomy and LAT since neither 
decortication nor any significant division of adhesions is undertaken during the latter.  
 
In conclusion, radiographic evidence of NEL after MPE drainage was frequently 
observed, but associated with poor inter-observer agreement in this multi-centre 
retrospective cohort study. In both cohorts studied, NEL was associated with adverse 
survival, although the independence of this relationship has not been proven here. These 
data should be considered in clinical decision-making and MPE trial design, particularly 
when single observers are used. Future studies should seek biomarkers for NEL that are 
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Table 1. Patient demographics, clinical characteristics and median overall survival in 
two independent malignant pleural effusion cohorts who underwent diagnostic Local 
Anaesthetic Thoracoscopy (LAT).  
IQR, interquartile range; CI, confidence interval; CUP, carcinoma of unknown primary; 
SCC, squamous cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; LDH, pleural 
fluid lactate dehydrogenase; NEL, non-expansile lung.





Age, mean (95% CI)  71 (69 - 74) 72 (70 - 75) 0.581 
Male, n (%)  65 (67) 69 (80) 0.047 
Right sided, n (%)  56 (58) 44 (51) 0.457 
Tumour type, n (%)     
Mesothelioma  56 (58) 64 (74) 0.012 
Lung   21 (22) 10 (12) 0.079 
Breast   6 (6) 5 (6) 0.999 
Genitourinary   5 (5) 2 (2) 0.450 
Gastrointestinal   3 (3) 3 (3) 0.999 
Haematological   1 (1) 0 (0) 0.999 
Other 5 (5) 2 (2) 0.450 
Performance status, n (%)     
0  18 (19) 14 (16) 0.702 
1  64 (66) 53 (62) 0.643 
2  9 (9) 16 (19) 0.085 
3  6 (6) 3 (3) 0.504 
NLR, median (IQR) 4.2 (2.8 - 5.9) 4.16 (2.79 - 5.29) 0.878 
LDH, median IU/mL (IQR) 0.36 (0.21 - 0.63) 0.52 (0.35 - 0.79) 0.003 
Total LENT score, median (IQR)  1 (1 - 3) 1.5 (1 - 2) 0.534 
Median overall survival, days (IQR) 267 (116 - 525) 360 (172 - 537) 0.122 
NEL, n (%) 33 (34) 15 (17) 0.012 
 
 
Table 2. Results of univariable and multivariable Cox regression analysis in two MPE cohorts. Multivariable model outputs report the 
association between predictors of overall survival (OS), including non-expansile lung (NEL) and individual components of the LENT prognostic 
score. Predictors independently associated with OS are highlighted in bold. 
 Univariable analysis Multivariable analysis 
 HR (95% CI) p HR (95% CI) p 
COHORT 1 (n=97)     
NEL 1.93 (1.21 – 3.06) 0.006 2.19 (1.31 – 3.66) 0.003 
LENT tumour score* 1.69 (1.31 – 2.19) 0.000 1.65 (1.24 – 2.19) 0.001 
Pleural fluid LDH (IU/mL) 1.29 (1.09 – 1.54) 0.004 1.25 (1.03 – 1.52) 0.025 
NLR 1.12 (1.04 – 1.21) 0.004 1.09 (1.01 – 1.18) 0.026 
ECOG PS 1.93 (1.40 – 2.67) 0.000 1.27 (0.88 – 1.85) 0.206 
COHORT 2 (n=86)     
NEL 2.08 (1.07 – 4.04) 0.032 1.42 (0.71 – 2.87) 0.322 
LENT tumour score* 1.78 (1.32 – 2.38) 0.000 2.24 (1.60 – 3.15) 0.000 
Pleural fluid LDH (IU/mL) 2.04 (1.37 – 3.05) 0.000 2.34 (1.50 – 3.64) 0.000 
NLR 1.00 (0.93 – 1.07) 0.916 0.95 (0.88 – 1.02) 0.173 
ECOG PS 1.26 (0.90 – 1.75) 0.184 1.27 (0.88 – 1.84) 0.197 
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NLR, neutrophil-to-lymphocyte 
ratio; LDH, lactate dehydrogenase; IU/mL, International Units/millilitre; NEL, non-expansile lung. * Tumour-type risk score used in ‘LENT’ 





Overall Survival stratified by lung re-expansion status (Expansile lung vs Non-expansile 
Lung (NEL)) following Local Anaesthetic Thoracoscopy (LAT) in 2 cohorts of patients with 
MPE (Cohort 1 n=97, Cohort 2 n=86).  
 
Figure 2 
Overall Survival stratified by extreme expansion phenotypes (Complete Non-expansile Lung 
(NEL)) vs Complete Expansion) following Local Anaesthetic Thoracoscopy (LAT) in a post 
hoc analysis of subgroups of Cohort 1 (n=25) and Cohort 2 (n=49). 
 
Figure 3 
Examples of lung re-expansion classification based on subjective visual estimation before 
and after complete malignant pleural effusion drainage at Local Anaesthetic Thoracoscopy 
(LAT): (a) NEL on basis of <50% pleural apposition, (b) Complete expansion (c) Complete 
NEL, in this case associated with modest surgical emphysema following LAT.   
 
 
 
